Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8 + T cell dysfunction and maintain memory phenotype

Synergistic CD8 + T cell activation by antibodies to PD-1 and GITR in cancer immunotherapy depends on the CD226 costimulatory pathway.